Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Biotech
Enliven calls time on phase 1 HER2 solid tumor program
Enliven won’t take its phase 1 solid tumor drug into further development next year.
James Waldron
May 15, 2025 7:50am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
Eisai's abandoned Enhertu challenger set to live on at BlissBio
Mar 21, 2025 7:20am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
OS' drug stopped lung cancer from returning in 3rd of patients
Jan 15, 2025 9:55am
Carisma axes sole clinical candidate, lays off 34% of staff
Dec 9, 2024 10:58am
